|
Phase I-Study of Weekly Bendamustin in Patients with Solid Tumors. |
|
|
Consulting or Advisory Role - Astellas Pharma; GlaxoSmithKline; Lilly/ImClone; Nanobiotix; Novartis; Pfizer; Roche/Genentech |
Speakers' Bureau - Novartis |
Research Funding - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Janssen Oncology; Lilly; Merck; Millennium; Nektar; Novartis; OncoMed; Pfizer; PharmaMar; PsiOxus Therapeutics; Puma Biotechnology; Roche/Genentech; Sanofi; Spectrum Pharmaceuticals |
Travel, Accommodations, Expenses - Lilly; Novartis; PsiOxus Therapeutics |
Other Relationship - Pierre Fabre |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Lilly; Merck Sharp & Dohme; Novartis; Roche; Takeda |
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Lilly; Merck Sharp & Dohme; Novartis; Roche; Takeda |
|
|
Consulting or Advisory Role - Pfizer; Roche/Genentech |
Speakers' Bureau - Novartis; Roche/Genentech |
Travel, Accommodations, Expenses - Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Janssen Research & Development |
|
|
Employment - Johnson & Johnson |
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
Employment - Johnson & Johnson |
Stock and Other Ownership Interests - Johnson & Johnson |
Travel, Accommodations, Expenses - Johnson & Johnson |
|
|
Employment - Johnson & Johnson |
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Genentech |
|